Dr. Muggia on Current Status of Intraperitoneal Therapy for Gynecologic Cancers

Video

Franco Muggia, MD, professor of Medicine, NYU Langone Medical Center, discusses the current status of intraperitoneal therapy for patients with gynecologic malignancies.

Franco Muggia, MD, professor of Medicine, NYU Langone Medical Center, discusses the current status of intraperitoneal (IP) therapy for patients with gynecologic malignancies.

IP therapy is a treatment with a demonstrated overall survival (OS) benefit, Muggia explains. However, it has not gained enough traction to become a go-to treatment. A recent study published in the Journal of Clinical Oncology showed that IP therapy should be used in ovarian cancer when optimal cytoreduction leads to minimal residual disease.

The published study also reported that there is an OS benefit with IP therapy, with a 25% hazard ratio for reduction of deaths.

<<<

View more from the 2015 CFS Annual Meeting

Related Videos
Gottfried Konecny, MD
Patrick I. Borgen, MD
Gottfried E. Konecny, MD, lead clinician, gynecologic oncology, Department of Medicine, the University of California, Los Angeles
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology